Table 1 Clinical characteristics of all included patients

n

18

34

10

15

10

10

Age, mean ± SD, yr

37.9 ± 8.3

42.9 ± 14.0

30.9 ± 13.9

29.8 ± 10.5

37.1 ± 13.1

42.4 ± 12.7

Sex, male/female

10/5

13/21

5/5

11/4

8/2

8/2

Disease duration, median (range)

12(6–240)

24(12–60)

24(10–120)

27(12–120)

27(9–120)

Montreal A (Age of onset, yr), n (%)

A1 (< 16)

0

1(6.7)

A2 (17 ~ 40)

8(80)

12(80)

A3 (> 40)

2 (20)

2(13.3)

Montreal A (Location), n (%)

L1 (ileal)

3(30)

5(33.3)

L2 (colonic)

4(40)

3(20)

L3 (ileocolonic)

3(30)

7(46.7)

L4 (upper gastrointestinal tract)

0

0

Montreal B (Behavior), n (%)

B1 (nonstricturing, nonpenetrating)

9(90)

13(86.7)

B2 (stricturing)

1(10)

1(6.7)

B3 (penetrating)

0

1(6.7)

Montreal E, n (%)

E1 (ulceration proctitis)

3(30)

3(30)

E2 (left-sided ulceration colitis)

3(30)

4(40)

E2 (extensive ulceration colitis)

4(40)

3(30)

Therapy, n (%)

5-ASA

2(20)

1(6.7)

8(80)

7(70)

Azathioprine

3(30)

2(13.3)

0(0)

0(0)

Steroids

0(0)

0(0)

2(20)

3(30)

Infliximab

5(50)

11(73.3)

0(0)

0(0)

Nutritional treatment

1(10)

2(13.3)

0(0)

0(0)